This study is testing a new treatment for leukemia, a type of cancer that affects white blood cells. It looks at how safe and effective a medicine called revumenib is when used with chemotherapy, which is a type of cancer treatment. This study is for young children whose leukemia has come back or hasn't responded to treatment and involves a specific change in their genes, called KMT2A rearrangement.
Key Points:
- This study involves several cycles of taking the medicine revumenib and chemotherapy, which can be given through the mouth or a tube.
- Participants will need to visit the hospital regularly for tests, including blood samples and scans, to check how the treatment is working and monitor for side effects.
- Participants must be under 6 years old, have a specific type of leukemia, and not have other health conditions like Down syndrome or certain infections.
It's important to discuss with doctors about the potential benefits and risks of participating, such as possible side effects and the commitment required for the study visits and treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand